No Data
No Data
NASDAQ New 52-Week Highs And Lows
Amgen, Garmin Among Relative Market Leaders Poised to Outperform in Coming Months: BTIG
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
Express News | Morgan Stanley Reports 10.3% Passive Stake in Arbutus Biopharma Corp as of May 31- SEC Filing
Express News | HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $5 Price Target
Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $4
No Data